There are 2789 resources available
718TiP - KEYNOTE-676 cohort B: Randomized comparator-controlled cohort to evaluate efficacy and safety of pembrolizumab (pembro) plus bacillus Calmette-Guérin (BCG) in patients with high-risk BCG treatment-naive non-muscle invasive bladder cancer (HR NMIBC)
Presenter: Shahrokh F. Shariat
Session: ePoster Display
719TiP - SunRISe-1: Phase IIb study of TAR-200 in combination with cetrelimab (CET), TAR-200 alone, or CET alone in participants with high risk non-muscle invasive bladder cancer unresponsive to intravesical bacillus Calmette-Guérin who are ineligible for or elected not to undergo radical cystectomy
Presenter: Michiel van der Heijden
Session: ePoster Display
891P - Landscape of NOTCH1 genomic alterations (GA) in head and neck squamous cell carcinoma (HNSCC) and T-ALL
Presenter: Kristian Ikenberg
Session: ePoster Display
765P - Prognosis of BRCA1 and BRCA2 ovarian cancer: Prospective follow-up data from a multidisciplinary program
Presenter: Pedro Antunes Meireles
Session: ePoster Display
766P - Mapping BRCA1/2 variants in ovarian cancer patients: Contribution of a BRCA2 founder effect
Presenter: Teresa Duarte
Session: ePoster Display
767P - Retrospective analysis of the impact of bevacizumab dose-intensity on the survival of platinum-resistant ovarian cancer patients
Presenter: Jose Bahena
Session: ePoster Display
689P - Human leukocyte antigen (HLA) class I/II expression as a predictive biomarker for response to immune oncology (IO) therapy in metastatic clear-cell renal cell carcinoma (m-ccRCC)
Presenter: Lisa Kinget
Session: ePoster Display
690P - Comprehensive genomic profiling (CGP) of VHL mutated and VHL wild type clear cell renal cell carcinoma (ccRCC)
Presenter: Gennady Bratslavsky
Session: ePoster Display
691P - Effect of NANOGNB mutations on DNA damage response and efficacy of immune checkpoint inhibitors in advanced renal clear cell carcinoma
Presenter: Zhiwen Luo
Session: ePoster Display
Resources:
Abstract
692P - Characterization of the tumor immune microenvironment in early-stage clear cell renal cell carcinoma (ccRCC): Prognostic value of an M0-macrophage enriched subtype
Presenter: Mark Farha
Session: ePoster Display